Narita M, Ashkin D, Hollander E, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998;158:157-161.


Olivia J, Moreno S, Sanz J, et al. Coadministration of rifampin and nevirapine in HIVinfected patients with tuberculosis. AIDS 2003;17:637-642.


Palella FJ, Jr., Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003; 138(8):620-626.

Patel A, Patel K, Patel J, et al. To study the safety and antiretroviral efficacy of rifampicin and efavirenz in antiretroviral-naïve tuberculosis coinfected HIV-1 patients in India. X Conference on Retroviruses and Opportunistic Infections; 2003; Boston, Massachusetts (Abstract 138).

Pedral-Samapio D, Alves C, Netto E, et al. Efficacy of efavirenz 600 mg dose in the ARV therapy regimen for HIV patients receiving rifampicin in the treatment of tuberculosis. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10-14; Boston, Massachusetts (Abstract 784).

Piliero PJ. Atazanavir: a novel HIV-1 protease inhibitor. Expert Opin Investig Drugs 2002; 11(9):1295-1301.

Pollard RB, Tierney C, Havlir D, et al. A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298). AIDS Res Hum Retroviruses 2002;18(10):699-704.


Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevaripine and rifampicin in HIV-infected patients with tuberculosis . J Acquir Immune Defic Syndr 2001;28:450-453.

Ribera E, Azuaje C, Montero F. Saquinavir, ritonavir, didanosine, and lamivudine in a once daily regimen for HIV infection in patients with rifampin-containing antituberculosis treatment. 14th International Conference on AIDS; 2002 Jul 7-12; Barcelona (Abstract ThPeB7280).


Sanne I, Piliero P, Squires K, et al. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviralnaive subjects. J Acquir Immune Defic Syndr 2003;32(1):18-29.

Santoro-Lopes G, de Pinho AM, Harrison LH, et al. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002;34(4):543-546.

Saulsbury FT. Resolution of organ-specific complications of human immunodeficiency virus infection in children with use of highly active antiretroviral therapy. Clin Infect Dis 2001;32:464-468.

Schaaf B, Aries SP, Kramme E, et al. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2003;37(3):41-43.

Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 Study . J Allergy Clin Immunol 2003; 112(5):973-980.

Smith NA, Shaw T, Berry N, et al. Antiretroviral therapy for HIV-2-infected patients. J Infect Dis 2001;42:126-133.

Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavirlamivudine-zidovudine in antiretroviral-naïve HIV-infected adults: A randomized equivalence trial. JAMA. 2001;285 (9):1155-1163.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement